Abstract:Despite recent clinical progress in peptide-based dual inhibitors of MDM2/4, small-molecule ones with robust antitumor activities remain challenging. To tackle this issue, 31 (YL93) was structure-based designed and synthesized, which had MDM2/4 binding Ki values of 1.1 and 642 nM, respectively. In three MDM4-overexpressing cancer cell lines harboring wild-type p53, 31 shows improved cell growth inhibition activities compared to RG7388, an MDM2-selective inhibitor in late-stage clinical trials. Mechanistic studies show that 31 increased cellular protein levels of p53 and p21 and upregulated the expression of p53-targeted genes in RKO cells with MDM4 amplification. In addition, 31 induced cell-cycle arrest and apoptosis in western blot and flow cytometry assays. Taken together, dual inhibition of MDM2/4 by 31 elicited stronger antitumor activities in vitro compared to selective MDM2 inhibitors in wild-type p53 and MDM4-overexpressing cancer cells.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00095.qPCR analysis of TP53 and MDM4 genes in RKO cells in the presence of YL93 for 24 h (Figure S1); flow cytometry figures of cell-cycle arrest upon treatment of RG7388 and Nutlin-3a for 24 h (Figure S2); flow cytometry figures of apoptosis induction upon treatment of Nutlin-3a for 48 h (Figure S3); efficacy studies in the RKO xenograft model in nude mice (Figure S4); western blot analysis of 31 (YL93) and RG7388 in HCT-116 cells (Figure S5); cell growth inhibition of YL93, YM129, RG7388, and Nutlin-3 in HEK-293 cells (Figure S6); pharmacokinetic parameters of YL93 in ICR mice (Table S1); and X-ray crystallography data of 57 (Table S2) (PDF)Molecular formula string (CSV)This article has not yet been cited by other publications.

Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein–Protein Interactions

Small Molecule Inhibitors of the P53-Mdm2

Recent Advances of P53-Mdm2 Small Molecule Inhibitors (2011-Present).

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Small-molecule MDM2 inhibitors in clinical trials for cancer therapy

MDM2: current research status and prospects of tumor treatment

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Pharmacologic Activation of P53 by Small-Molecule MDM2 Antagonists.

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

An update patent review of MDM2-p53 interaction inhibitors (2019-2023)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction.

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy

Structural effects and competition mechanisms targeting the interactions between p53 and MDM2 for cancer therapy

The Discovery of Potential MDM2 Inhibitors: A Combination of Pharmacophore Modeling, Virtual Screening, Molecular Docking Studies, and in vitro/in vivo Biological Evaluation

Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents